The Association of GSTT1, GSTM1, and TNF-α Polymorphisms With the Risk and Outcome in Multiple Myeloma-Reference-Cited by-同舟云学术

The Association of GSTT1, GSTM1, and TNF-α Polymorphisms With the Risk and Outcome in Multiple Myeloma

Published:2019-10-11 Issue: Volume:9 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Zmorzyński Szymon,Popek-Marciniec Sylwia,Szudy-Szczyrek Aneta,Wojcierowska-Litwin Magdalena,Korszeń-Pilecka Iwona,Chocholska Sylwia,Styk Wojciech,Hus Marek,Filip Agata A.

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference49 articles.

1. Plasma cell differentiation and multiple myeloma;Shapiro-Shelef;Curr Opin Immunol.,2004

2. Genetics of multiple myeloma: another heterogeneity level?;Corre;Blood.,2015

3. Targeting ongoing dna damage in multiple myeloma: effects of dna damage response inhibitors on plasma cell survival;Herrero;Front Oncol.,2017

4. DNA repair, dysregulation from cancer driver to therapeutic target;Curtin;Nat Rev Cancer.,2012

5. Glutathione transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases;Allocati;Oncogenesis.,2018

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In Vitro Low-Bortezomib Doses Induce Apoptosis and Independently Decrease the Activities of Glutathione S-Transferase and Glutathione Peroxidase in Multiple Myeloma, Taking into Account the GSTT1 and GSTM1 Gene Variants;Genes;2024-03-21

2. Analysis of Mutational Status of IGHV, and Cytokine Polymorphisms as Prognostic Factors in Chronic Lymphocytic Leukemia: The Romanian Experience;International Journal of Molecular Sciences;2024-02-01

3. Challenges and Future of Cancer Pharmacogenetics;Handbook of Oncobiology: From Basic to Clinical Sciences;2024

4. Ferroptosis of macrophages facilitates bone loss in apical periodontitis via NRF2/FSP1/ROS pathway;Free Radical Biology and Medicine;2023-11

5. Association of Chromosome 17 Aneuploidy, TP53 Deletion, Expression and Its rs1042522 Variant with Multiple Myeloma Risk and Response to Thalidomide/Bortezomib Treatment;Cancers;2023-09-27